• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BioNTech, Ganymed Pharmaceuticals open research headquarters in Germany

BioNTech, Ganymed Pharmaceuticals open research headquarters in Germany

October 2, 2014
CenterWatch Staff

BioNTech and Ganymed Pharmaceuticals, two German biotechology companies, have opened a 108,000-square-foot headquarters and research facility. The new facility brings together 300 employees and is located near academic institutions, hospitals and cancer research institutions.

BioNTech and Ganymed scientists will work in state-of-the-art lab space on a range of preclinical and clinical programs mainly in the field of highly personalized cancer therapies.

Founded in 2008, BioNTech develops and produces individualized cancer immunotherapies with a focus on novel and disruptive technologies, such as mRNA-based biologicals or innovative antigen-receptor/T-cell-receptor therapies. BioNTech is organized into six fully-integrated companies including a cGMP production site for gene and cell therapy and RNA therapeutic products. BioNTech has 300 employees, of which over 200 will be based in the new research facility.

Ganymed—a spin-off in 2001 from the Universities of Mainz and Zurich—currently has 90 employees located in Mainz. Its highly selective antibody (IMAB362) against stomach/esophagus cancer is in advanced stages of clinical trials. After the majority of 21 patients treated in a phase IIa trial showed a significant slow-down of the cancer, Ganymed recruited 210 patients for a phase IIb trial. In addition, a second antibody (IMAB027) against ovary cancer entered phase I/II trials in early 2014.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing